TCT-195 Outcomes of emergent percutaneous cardiopulmonary support in cardiac or respiratory failure: Comparisons of cardiac versus non-cardiac failure  by Kwon, Sung UK.
B74 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5initiated semi-electively in 1 case. In the other 6 cases, the average
time from decision to cannulation was 43 hrs (range 2-10 hours).
The average duration of VA-ECMO was 6.165.5 days (range 3 hours
to 14 days). Access related complication occurred in 2 cases (1 major
bleeding, 1 leg ischemia). Death occurred in 71.4% (5 patients).Indications and Outcomes of IABP
INDICATIONS TOTAL n(%) 2010 2011 2012 2013 2014@
MORTALITY
n(%)#
Post myocardial
infarction (MI)
cardiogenic shock
95 (42.8%) 14 17 21 23 20 44 (46%)
Pre-operative support
for cardiac surgery
75 (33.8%) 18 14 17 20 6 5 (6.7%)
High risk/complicated
angioplasty/
catheterization*
41 (18.4%) 10 9 5 11 6 7 (17%)
Complications of MI
ˇ
4 (1.8%) 1 0 2 1 0 3 (75%)
Refractory post MI
angina
4 (1.8%) 2 1 0 1 0 1 (25%)
Refractory left
ventricular failure
2 (0.9%) 1 0 1 0 0 0
Refractory ventricular
arrhythmias
1 (0.5%) 0 0 0 1 0 0
222 (100%) 46 41 46 57 32 60 (27.4%)
*left main stenting, dissections, STEMI without CS, severe triple vessel disease,
ˇ
ventricular septal defect,
papillary muscle rupture, #in hospital all-cause mortality, @9 months data only.CONCLUSIONS In our experience, IABP was most commonly utilized
in CS complicating myocardial infarction. The trend of use for this
indication does not seem to have reduced after IABP-SHOCK II. Over
half of the IABPs inserted were for indications other than CS. VA-
ECMO may be life-saving treatment after failure of IABP support in
shocked patients. Appropriate patient selection for VA-ECMO is
challenging. Clinical trial of IABP may aid patient triage
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BACKGROUND Percutaneous cardiopulmonary support (PCPS) is a
widely accepted treatment for severe cardiopulmonary failure
because this system can be rapidly applied in emergency situations.
However, there is no available data on clinical outcome in patients
between cardiac and non-cardiac origin cardiopulmonary failure.
METHODS We analyzed 61 consecutive patients with severe cardio-
pulmonary failure and complicating cardiogenic shock who were
assisted by an emergent bypass system (EBSTerumo, Tokyo, Japan)
between January 2012 and May 2015. The primary outcome was the
success rate of weaning from EBS. The secondary outcome was in-
hospital mortality.
RESULTS The mean duration of PCPS was 77.6 hours and that of car-
diopulmonary resuscitation (CPR) was 32 (52.5%). The rate of weaning
was 23 (37.7%) and the rate of weaning from cardiac group was higher
than non-cardiac group (51.2% vs. 10.0%, p¼0.002). In-hospital mor-
tality occurred for 45 patients (63.4% vs. 95.0%, p¼0.012).Table 1. Univariate analysis between cardiac and non-cardiac groupCardiac (n[41) Non-cardiac (n[20) p-valueAge (years) 63.7  12.4 54.8  15.0 0.017
Sex, male (%) 29 (70.7) 14 (70.0) 1.000BMI (Kg/m2) 23.5  3.7 23.6  4.0 0.965
APACHEII score 16.2  9.8 21.8  12.7 0.068
Mean BP (mmHg) 78.0  13.5 79.6  25.6 0.754
Ejection Fraction (%) 40.4  16.8 51.6  13.5 0.017
Estimated GFR 49.5  33.8 39.7  23.5 0.271
Troponin I (ng/mL) 33.9  51.4 9.4  35.1 0.071
CRRT (%) 16 (39.0) 14 (70.0) 0.031Vasopressor (%) 41 (100) 18 (90.0) 0.104CPR (%) 18 (43.9) 14 (70.0) 0.064Weaning (%) 21 (51.2) 2 (10.0) 0.002ECMO time (hours) 79.5  14.1 67.9  19.9 0.641CONCLUSIONS Cardiopulmonary failure with non-cardiac origin was
associated with high mortality. An APACHE II score & renal replace-
ment therapy might serve as outcome for risk stratiﬁcation.
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BACKGROUND No studies have explored hemodynamic variables
associated with right ventricular dysfunction (RVD) in the The SHould
we emergently revascularize Occluded coronaries for Cardiogenic
shock (SHOCK) trial and registry including: central venous pressure
(CVP), CVP/pulmonary capillary wedge pressure (PCWP) ratio, pul-
monary artery pulsatility index (PAPi), and right ventricular stroke
work index(RVSWI). The Recover Right Trial deﬁned RV failure using
three variables (RR-RVF Criteria) including a cardiac index < 2.2, CVP
> 15 or CVP/PCWP>0.63, or use of an inotrope or vasopressor. We
explored the hypothesis that RVD is common and contributes to
higher mortality in the setting of acute myocardial infarction
complicated by cariogenic shock (AMI-CS).
